These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 7882329)
1. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice. Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329 [TBL] [Abstract][Full Text] [Related]
2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328 [TBL] [Abstract][Full Text] [Related]
3. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans. Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505 [TBL] [Abstract][Full Text] [Related]
4. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites. Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504 [TBL] [Abstract][Full Text] [Related]
5. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454 [TBL] [Abstract][Full Text] [Related]
6. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995 [TBL] [Abstract][Full Text] [Related]
7. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471 [TBL] [Abstract][Full Text] [Related]
8. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Arakawa H; Morita M; Kodera T; Okura A; Ohkubo M; Morishima H; Nishimura S Jpn J Cancer Res; 1999 Oct; 90(10):1163-70. PubMed ID: 10595746 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602 [TBL] [Abstract][Full Text] [Related]
10. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model. Balasubramanian BN; St Laurent DR; Saulnier MG; Long BH; Bachand C; Beaulieu F; Clarke W; Deshpande M; Eummer J; Fairchild CR; Frennesson DB; Kramer R; Lee FY; Mahler M; Martel A; Naidu BN; Rose WC; Russell J; Ruediger E; Solomon C; Stoffan KM; Wong H; Wright JJ; Zimmermann K; Vyas DM J Med Chem; 2004 Mar; 47(7):1609-12. PubMed ID: 15027851 [TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
13. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cavazos CM; Keir ST; Yoshinari T; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 2001 Sep; 48(3):250-4. PubMed ID: 11592348 [TBL] [Abstract][Full Text] [Related]
15. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146 [TBL] [Abstract][Full Text] [Related]
17. ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Arakawa H; Iguchi T; Yoshinari T; Kojiri K; Suda H; Okura A Jpn J Cancer Res; 1993 May; 84(5):574-81. PubMed ID: 8320174 [TBL] [Abstract][Full Text] [Related]
18. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285 [TBL] [Abstract][Full Text] [Related]